Research programme: ROR gammaT antagonists - ImmunicAlternative Names: IMU-366
Latest Information Update: 05 Oct 2016
At a glance
- Originator 4SC
- Developer Immunic
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Immunological disorders; Inflammatory bowel diseases; Psoriasis